IFRX News

Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long term historical average of 13%. The week featured three regional banks, three biotechs, three fast-growing Chinese companies and a communications platform pivoting to growth. First day...read more

InflaRx, which is developing an antibody for rare autoimmune and inflammatory diseases, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders are buying $40 million (40% of the deal) on the offering. InflaRx plans to list on the Nasdaq under the symbol IFRX. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as lead...read more

An active 4Q17 powers ahead with 11 IPOs scheduled to raise $2.0 billion in the coming week. That would make it the IPO market's busiest week of the year. The activity level is unsurprising given the 32 new filings in October, a two-year high. We also expect a number of IPOs to launch this week in order to price before Thanksgiving.  China's recent surge of US IPOs...read more

Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, announced terms for its IPO on Monday. The Crestwood, KY-based company plans to raise $150 million by offering 10.7 million shares at a price range of $13 to $15. Insiders intend to purchase $70 million worth of shares in the offering (47% of offering). At the...read more